Ascendis jumps on Phase III readout for once-weekly growth hormone

Ascendis gained $54.16 (78%) to $123.47 in afternoon trading Monday after reporting that its TransCon Growth Hormone met the primary endpoint in the Phase III heiGHt trial to treat pediatric growth hormone deficiency. The company plans to submit a BLA to FDA in 1H20 for the once-weekly human growth hormone (hGH) prodrug that uses TransCon prodrug technology for sustained release.